$AZN wonder what will happen when PFE gives up on offers, AZN will then be a "bag holder" of sorts...not sure how market will respond

-- tlhwn (@tlhwn) May. 2 at 07:13 AM

AstraZeneca has several drugs in late-stage clinical trials that management believes make it worth more than $106 billion. It has 14 compounds to treat various cancers, including thyroid, ovarian and leukemia, in Phase III trials. It also has four cardiovascular and metabolism drugs under development and several drugs targeting infections.

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting